Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality-of-life with Plenadren vs Cortison in newly diagnosed primary adrenal insufficiency
2021-006487-24Phase 4Active
- Sponsor
- Helse Bergen
- Start
- Oct 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydrocortisone and cortisone in Addison's disease (2 arms), sponsored by Helse Bergen. Primary endpoint: Primary Endpoint: Health-related quality of life (HRQoL) at 12 months. Started Oct 2022; status: active.
02
Drugs
hydrocortisonecortisone
03
Conditions
Addison's disease
Beyond the preview
Go deeper on 2021-006487-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006487-24.